

Curriculum Vitae Emmanuel SERONT

Last name: SERONT

First name: Emmanuel

Birth date and place: 24/07/1979, La Louvière, Belgium

Adress: Chaussée de Tubize 121, 1440 Braine le Chateau, Belgium

Tel : +32 475/ 942047

Universitary cursus

First Doctorat: Magna Cum Laude, June 2001

Second Doctorat: Magna Cum Laude, June 2002

Third Doctorat: Magna Cum Laude, June 2003

Fourth Doctorat: Magna Cum Laude, June 2004

EKG certificate, June 2003

Medical Doctor , June 2004 with Magna Cum Laude

Doctor in pharmaceutical and biomedical science (PhD), November 2013

Internal Medicine Fellowship

- 2004-2005 : Hopital de Jolimont, Dr Derue, Haine Saint Pierre, Belgium
- 2005-2006 : Hopital de Gilly, Dr Mineur , Gilly, Belgium
- 2006-2007 : Hopital Universitaire Saint Luc, Medical Oncology, Prof Machiels, Belgium
- 2007-2008 : Hopital Universitaire Saint Luc, Nephrology unit, Prof Jadoul, Belgium
- 2008-2008 : Hopital Universitaire Saint Luc, Intensive care Unit, Prof Laterre

Oncology Fellowship

- 2008-2009 : Hopital Universitaire Saint Luc, Medical Oncology, Prof Machiels
- 2009- 2013: Training Fellow in fondamental research in oncology and experimental pharmacotherapy with a PhD project “ Role of mTOR inhibitor in cancer; link with autophagy, hypoxia and angiogenesis.”

Postgraduate Course of Medical Oncology, National Oncology Examination

2009= 83%

2010= 85%

2011= 86%

Certificate of Good Clinical Research Practice (April 2013)

Certificat universitaire en science et médecine des animaux de laboratoire, « Maître en expérimentation animale » UCL

Diploma of Doctor in Pharmaceutical and Biomedical Sciences (PhD) 19 Novembre 2013

“Dealing with resistances to mTOR inhibitors in bladder and breast cancer. “

Thesis presented in November 2013 at UCL, Brussel.

Promoter: Prof Feron O. and Machiels JP.

Formation légale en science et médecine des animaux de laboratoire (Février 2010)

Diplôme de “Maîtrise d’expérience” en expérimentation animale (June 2010)

Publications

- **About two intra aortic masses.**
E. Seront, G. de Saint Hubert, Derue G. European Journal of Internal Medicine, 2008
- **Targeted therapy in metastatic renal cell carcinoma.**
E. Seront, JP Machiels. Journal of Belgian Society of Medical Oncology, January 2008.
- **Review of angiogenesis inhibitors in renal cell carcinoma.**
E. Seront, JP Machiels. Recent Patents Anticancer Drug Discov, June 2009
- **Successful long-term management of a patient with late-stage metastatic colorectal cancer treated with panitumumab.**
E. Seront E, Marot L, Coche E, Gala JL, Sempoux C, Humblet Y. Cancer Treat Rev. 2010 Feb;36 Suppl 1:S11-4.
- **Update in malignant Melanoma.**
E. Seront and JF Baurain. Journal of Belgian Society of Medical Oncology, May 2010.
- **New therapeutic perspective in renal cell carcinoma: Everolimus.**
E. Seront and JP Machiels. Louvain Medical 2010
- **New drugs in medical oncology: new difficulties to distinguish drug-induced side effects from cancer complications: a case-report.**
E. Seront, F. Mazzeo, M. Mano, JP Machiels, JF Baurain. Acta Clinica Belgica 2011
- **Liver-Directed Therapies: Does It Make Sense in the Current Therapeutic Strategy for Patients With Confined Liver Colorectal Metastases?**
E. Seront, Van den Eynde M. Clin Colorectal Cancer. 2012
- **Phase II trial of Everolimus monotherapy in the palliative treatment of patients with metastatic Transitional Cell Carcinoma after failure of platinum-based therapy: activity and biomarkers.**
E. Seront, S. Rottey, B. Sautois, L. A. D'Hondt, J. L. R. Canon, J. M. Vandebulcke, N. Whenham, J. C. Goeminne, O. Feron, J. P. H. Machiels. Annals Oncology 2012
- **PTEN deficiency is associated with reduced sensitivity to mTOR inhibitor in human bladder cancer through the unhampered feedback loop driving PI3K/Akt activation.**
E. Seront, A. Pinto, C. Bouzin, JP Machiels, O. Feron. British Journal of Cancer September 2013.
- **Tumour hypoxia determines the potential of combining mTOR and autophagy inhibitors to treat mammary tumours.**
E. Seront, R. Boidot, O. Karroum, C. Bouzin, JP Machiels, O. Feron. British Journal of Cancer November 2013
- **Antitumor activity of 7-aminocarboxycoumarin derivatives, a new class of potent inhibitors of lactate influx but not efflux.**

Draoui N, Schicke O, *E. Seront*, Bouzin C, Sonveaux P, Riant O, Feron O.
Molecular Cancer Therapeutic March 2014

- **Molecular biology and targeted therapies for urothelial carcinoma.**
Seront E, Machiels JP. *Cancer Treatment Review 2015*
- **Updates in Renal Cell carcinoma : new targeted therapies and new toxicities.**
E. Seront, JP Machiels. *Book Chapter, Recent Patent Anticancer Drugs Discoveries 2012.*
- **Translation and Its Regulation in Cancer Biology and Medicine.** A. Parsyan, *E. Seront*, JP Machiels. *Book on Translation and Its Regulation in Cancer Biology and Medicine 2014.*
- **Venous Malformation: from causative mutations to murine model and targeted therapy.** E. Boscolo, N. Limaye, L. Huang, K. Kang, J. Soblet, M. Uebelhoer, A. Mendola, M. Natynki, *E. Seront*, S. Dupont, J. Hammer, C. Legrand, C. Brugnara, L. Eklund, M. Vikkula, J. Bischoff, L. Boon. *Journal of Clinical Investigation 2015.*
- **Rapid and fatal acute heart failure induced by pazopanib.** van Marcke C, Ledoux B, Petit B, Seront E. *British Medical Journal Case Rep 2015*
- **Rapamycin as Novel Treatment for Refractory-to-Standard-Care Slow-Flow Vascular Malformations.** Boon LM, Hammer J, *Seront E*, Dupont S, Hammer F, Clapuyt P, Vikkula M. *Plast Reconstr Surg. 2015*
- **Phase II study of dual phosphoinositol-3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor BEZ235 in patients with locally advanced or metastatic transitional cell carcinoma (TCC).** *Seront E*, Rottey S, Filleul B, Glorieux P, Goeminne J, Verschaeve V, Vandenbulcke JM, Sautois B, Boegner P, Gillain A, van Maanen A, Machiels JP. *British Journal of Urology. 2016 Jan*
- **Unusual presentation of bladder cancer resurgence and efficacy of radiotherapy.** Galot R, Christian N, Bitar M, *Seront E*. *BMJ Case Rep. 2016 Jan 27;2016.*
- **Atypical case of ecthyma gangrenosum mimicking a breast cancer recurrence.**
Seront E, Kidd F, Metz T, Van Ruyseveldt P. *BMJ Case Rep. 2016 Mar 30;2016.*
- **Rapamycin opens the era of targeted molecular therapy of venous malformations.** *Seront E*, Limaye N, Boon LM, Vikkula M. *Med Sci (Paris). 2016 Jun-Jul;32(6-7):574-8.*
- **Randomized Phase II Study of Cabazitaxel Versus Methotrexate in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With Platinum-Based Therapy.** Machiels JH, Van Maanen A, Vandenbulcke JM, Filleul B, *Seront E* et al. *Oncologist. 2016 Nov 30.*

- **Targeting the Human Epidermal Receptor family in squamous cell carcinoma of the head and neck.** *Seront E* and Machiels JP. Head and neck cancer: evidence-based treatment. Book chapter 2017 (submitted)
- **Palmar fasciitis and polyarthritis, a rare paraneoplastic syndrome related to ovarian cancer.** van Marcke C, *Seront E*, Docquier C, Filleul B. Clin Exp Dermatol. 2017 Apr;42(3):328-330
- **Venous Malformations of the Head and Neck.** *Seront E*, Vikkula M, Boon LM. Otolaryngol Clin North Am. 2018 Feb;51(1):173-184
- **Venous Malformations.** *Seront E*, Vikkula M, Boon LM. Uptodate chapter 2017
- **Immune checkpoint inhibitors as a real hope in advanced urothelial carcinoma.** *Seront E*, Lejeune S, Catala G, Dermine A, Rysselink S. Future Science OA. October 2018
- **Rapamycin and treatment of venous malformations.** *Seront E*, Van Damme A, Boon LM, Vikkula M. Curr Opin Hematol. 2019 Mar 6
- **Phase 1 Study Evaluating the Association of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib and Cetuximab in Recurrent/Metastatic p16-negative Squamous Cell Carcinoma of the Head and Neck,** Seront E et al. Frontiers in Oncology, section Head and Neck Cancer.
- **Cascade of immunologic adverse events related to pembrolizumab treatment.** Dhenin A, Samartzi V, Lejeune S, *Seront E*. BMJ Case Rep. 2019 Jun 4;12(6)
- **May we rely on induction chemotherapy again as a biological selection of radiosensitive head and neck cancer?** Bossi P, *Seront E*, Machiels JP. Oral Oncol. 2019 Jul;94:121-122.
- **Isolated adrenocorticotrophic hormone (ACTH) deficiency and Guillain-Barré syndrome occurring in a patient treated with nivolumab.** Pierrard J, Petit B, Lejeune S, *Seront E*. BMJ Case Rep. 2019 Aug 21;12(8).
- **c-MET as a Potential Resistance Mechanism to Everolimus in Breast Cancer: From a Case Report to Patient Cohort Analysis.** Van den Bossche V, Jadot G, Grisay G, Pierrard J, Honoré N, Petit B, Augusto D, Sauvage S, Laes JF, Seront E. Target Oncol. 2020 Feb;15(1):139-146.
- **Impact of the gut microbiome on immune checkpoint inhibitor efficacy-a systematic review.** Pierrard J, Seront E. Curr Oncol. 2019 Dec;26(6):395-403.

- **Factor V and prothrombin polymorphism in patients aged 75 years or older.**
Abstract *E. Seront, J. Yango, O. Descamps. Acta Clinica Belgica, Vol 60 2005.*
- **Phase II trial of RAD001 monotherapy in the palliative treatment of patients with metastatic Transitional Cell Carcinoma after failure of platinum-based therapy.**
American Society of Clinical Oncology 2010 (Chicago), abstract
- **Phase II trial of Everolimus monotherapy in the palliative treatment of patients with metastatic Transitional Cell Carcinoma after failure of platinum-based therapy: activity and biomarkers.** American Society of Clinical Oncology 2011 (Chicago), Poster session.
- **Phase II trial of Everolimus monotherapy in the palliative treatment of patients with metastatic Transitional Cell Carcinoma after failure of platinum-based therapy: activity and biomarkers.** Belgian society of Medical Oncology 2011, oral presentation.
- **Angiogenesis-related cytokines as potential predictive biomarkers in a phase II trial evaluating everolimus efficacy in locally advanced or metastatic Transitional Carcinoma Cell.** Fifth European Organisation for Research and Treatment of Cancer (EORTC)/National Cancer Institute (NCI)/American Society of Clinical Oncology (ASCO) annual meeting on Molecular Markers in Cancer, Brussels 2011, poster session.
- **Translational research; analysis of RAD001 efficacy in patients with metastatic transitional cell carcinoma.** Fond National de la Recherche Scientifique - Télévie 2012 Liège, oral presentation
- **About translational research in metastatic bladder cancer.** European Urology Tour 2012 Brussel, oral presentation
- **Role of Akt activation induced by mTOR inhibitors in development of resistance to mTOR inhibitors.** Belgian Association of Cancer Research 2013, oral presentation.
- **Role of Akt activation induced by mTOR inhibitors in development of resistance to mTOR inhibitors.** Belgian Society of Medical Oncology 2013, oral presentation.
- **Hypoxia decreases efficacy of mTOR inhibitors in MCF-7: role of autophagy**
Belgian Association Cancer Research 2013 Antwerpen, poster presentation
- **Role of autophagy in cancer cells resistance to mTOR inhibitors.** Télévie 2012 Brussel, oral presentation and poster session
- **Multidisciplinary symposium Head and Neck symposium June 2014,** oral presentation.
- **Multidisciplinary symposium Head and Neck symposium May 2015,** oral presentation.

- **Phase II study of dual phosphoinositol-3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor BEZ235 in patients with locally advanced or metastatic transitional cell carcinoma (TCC).** American Society of Clinical Oncology 2015 (Chicago), abstract
- **Randomized phase II study of cabazitaxel versus methotrexate in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) previously treated with platinum-based therapy.** American Society of Clinical Oncology 2015 (Chicago), Poster presentation.
- **Preceptorship Program on Prostate Cancer** June 2015 (Cliniques Saint Luc)
- **Definitive chemoradiotherapy with either high-dose or weekly cisplatin in patients with locally advanced squamous cell head and neck cancer: A retrospective analysis.** European Society of Medical Oncology congress 2015, Vienna. Poster presentation
- **Phase I study of RibocicliB plus cetuximab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN).** European Society of Medical Oncology congress 2016, Copenhagen. Poster presentation.
- **Retrospective analysis of definitive chemoradiotherapy with either high-dose or weekly cisplatin in patients with locally advanced squamous cell head and neck cancer : 2-year outcome.** ECCO2017
- **Post ASCO GU.** Oral presentation Belgian Multidisciplinary Urological Cancer (BMUC) 2016
- **Multidisciplinary symposium** Head and Neck symposium May 2016, oral presentation.
- **Multidisciplinary symposium** Head and Neck symposium May 2017, oral presentation.
- **Immunotherapy in bladder cancer .** Oral presentation Belgian Multidisciplinary Urological Cancer (BMUC) 2017
- **Immunotherapy in bladder cancer .** Oral presentation Belgian Society of Medical Oncology (BSMO) 2018
- **The docetaxel-abiraterone acetate sequence compared to the abiraterone acetate-docetaxel sequence in metastatic castration-resistant prostate cancer patients with a response to previous castration superior to 12 months.** Poster presented at ASCO-GU 2018 (San Francisco)
- **A guided and personalized treatment in metastatic breast cancer: optimisation of gene and protein expression in tumor tissue.** Poster presented at ESMO 2018
- **A phase III trial evaluating sirolimus in vascular Malformations.** Oral presentation ISSVA 2018

- **Multidisciplinary symposium** Head and Neck symposium January 2019, oral presentation.
- **Post ASCO GU.** Oral presentation Belgian Multidisciplinary Urological Cancer (BMUC) 2018
- **Post ASCO GU.** Oral presentation Belgian Multidisciplinary Urological Cancer (BMUC) 2019
- **JOUM 2019** : oral presentation
- **Multidisciplinary symposium** Head and Neck symposium January 2020, oral presentation.
 - **c-MET as a Potential Resistance Mechanism to Everolimus in Breast Cancer: From a Case Report to Patient Cohort Analysis.** Van den Bossche V, Jadot G, Grisay G, Pierrard J, Honoré N, Petit B, Augusto D, Sauvage S, Laes JF, Seront E. Target Oncol. 2020 Feb;15(1):139-146.

Awards

- **Phase II trial of Everolimus monotherapy in the palliative treatment of patients with metastatic Transitional Cell Carcinoma after failure of platinum-based therapy: activity and biomarkers.** Oral presentation Belgian society of Medical Oncology, Junior Presentation Awards le 19 février 2011. First Award
- **Role of Akt activation induced by mTOR inhibitors in development of resistance to mTOR inhibitors.** Belgian Society of Medical Oncology 2013, oral presentation. First Award
- **Role of Akt activation induced by mTOR inhibitors in development of resistance to mTOR inhibitors.** Belgian Association of Cancer Research 2013, oral presentation. Second Award
- **Pfizer Educational Grant.** December 2013
- **John Mulliken Award for Best Scientific Paper: Venous Malformation: from causative TIE2 mutations to murine model and targeted therapy.** E. Boscolo, K. Kang, N. Limaye, J. Soblet, M. Uebelhoer, M. Natynki, C. Brugnara, E. Seront, L. Eklund, M. Vikkula, L. Boon. February 2015

Association Member

- American Society of Clinical Oncology (ASCO) member (2013)

- European Society of Medical Oncology (ESMO) member (2014)
- Belgian Society of Medical Oncology (BSMO) member (2013)
- Fonds de la recherche médicale en Hainaut (FRMH) member (2016)
- International Society for the Study of Vascular Anomalies (ISSVA) member (2018)

Current Position

- Medical oncologist at Hôpital de Jolimont, Groupe Jolimont (2/10/2013 till present)
- Head of Breast Clinic Hôpital de Nivelles (groupe Jolimont)
- Medical oncologist, Cliniques Universitaires Saint Luc, Brussel (consultant externe) (2/10/2013 till present)
- Coordinator of Onco-Urology at Cliniques Saint Luc , Brussel
- Nurse oncology course professor pour Haute Ecole Louvain en Hainaut (HeLHA)
- Referent oncologist for the vascular malformation center (VASCAPA) in Cliniques universitaires Saint Luc, Brussels, Belgium